Alissa Eckert, MSMI; Dan Higgins, MAMS
Since January 2020, we have worked aggressively to address the COVID-19 pandemic by utilizing our strengths in protein engineering and rapid protein expression in Nicotiana benthamiana plants. We have developed an array of proteins and technologies for potential therapeutic, diagnostic, research, and manufacturing applications to help in the fight against SARS-CoV-2:
- Monoclonal antibodies: broadly reactive anti-SARS CR3022 and engineered variants to improve binding and expression
- Nanobodies: camelids and camelid fusions against SARS-COV-2
- Viral glycoproteins: recombinant SARS-CoV-2 protein antigens
- Human interferons: We are producing a type I interferon that we believe could become an important antiviral tool for helping our bodies to combat current and future pandemic viruses
Our plant-made antibodies and other recombinant proteins are all highly purified and animal-free. For more information on our SARS-CoV-2 products listed above, including bulk orders of the CR3022 antibody, please contact info@novicibiotech.com.